Institute of Bioengineering and Nanotechnology, Singapore 138669, Singapore.
Biomaterials. 2012 Apr;33(10):2971-9. doi: 10.1016/j.biomaterials.2011.11.035. Epub 2012 Jan 13.
A new series of acid- and urea-functionalized polycarbonate block copolymers were synthesized via organocatalytic living ring-opening polymerization using methoxy poly(ethylene glycol) (PEG) as a macroinitiator to form micelles as drug delivery carriers. The micelles were characterized for critical micelle concentration, particle size and size distribution, kinetic stability and loading capacity for a model anticancer drug, doxorubicin (DOX) having an amine group. The acid/urea groups were placed in block forms (i.e. acid as the middle block or the end block) or randomly distributed in the polycarbonate block to investigate molecular structure effect. The micelles formed from the polymers in both random and block forms provided high drug loading capacity due to strong ionic interaction between the acid in the polymer and the amine in DOX. However, the polymers with acid and urea groups placed in the block forms formed micelles with wider size distribution (two size populations), and their DOX-loaded micelles were less stable. The number of acid/urea groups in the random form was further varied from 5 to 8, 13 and 19 to study its effects on self-assembly behaviors and DOX loading. An increased number of acid/urea groups yielded DOX-loaded micelles with smaller size and enhanced kinetic stability because of improved inter-molecular polycarbonate-polycarbonate (urea-urea and urea-acid) hydrogen-bonding and polycarbonate-DOX (acid-amine) ionic interactions. However, when the number of acid/urea groups was 13 or higher, micelles aggregated in a serum-containing medium, and freeze-dried DOX-loaded micelles were unable to re-disperse in an aqueous solution. Among all the polymers synthesized in this study, 1b with 8 acid/urea groups in the random form had the optimum properties. In vitro release studies showed that DOX release from 1b micelles was sustained over 7 h without significant initial burst release. MTT assays demonstrated that the polymer was not toxic towards HepG2 and HEK293 cells. Importantly, DOX-loaded micelles were potent against HepG2 cells with IC(50) of 0.26 mg/L, comparable to that of free DOX (IC(50): 0.20 mg/L). In addition, DOX-loaded 1b micelles yielded lower DOX content in the heart tissue of the tested mice as compared to free DOX formulation after i.v. injection. These findings signify that 1b micelles may be a promising carrier for delivery of anticancer drugs that contain amine groups.
一种新的酸和脲基功能化聚碳酸酯嵌段共聚物通过使用甲氧基聚(乙二醇)(PEG)作为大分子引发剂的有机催化活性开环聚合反应合成,以形成胶束作为药物输送载体。对胶束的临界胶束浓度、粒径和粒径分布、动力学稳定性和模型抗癌药物阿霉素(DOX)的载药量进行了表征,DOX 具有氨基。酸/脲基被放置在嵌段形式(即酸作为中间嵌段或末端嵌段)或随机分布在聚碳酸酯嵌段中,以研究分子结构的影响。聚合物在无规和嵌段形式中形成的胶束由于聚合物中的酸与 DOX 中的胺之间的强离子相互作用而具有高的药物载药量。然而,具有酸和脲基的聚合物在嵌段形式中形成的胶束具有更宽的粒径分布(两种粒径群体),并且其载有 DOX 的胶束不太稳定。进一步将无规形式中的酸/脲基的数量从 5 变化到 8、13 和 19,以研究其对自组装行为和 DOX 负载的影响。由于提高了聚碳酸酯-聚碳酸酯(脲-脲和脲-酸)氢键和聚碳酸酯-DOX(酸-胺)离子相互作用的分子间相互作用,增加了酸/脲基的数量,得到了粒径更小、动力学稳定性增强的 DOX 载药胶束。然而,当酸/脲基的数量为 13 或更高时,胶束在含有血清的介质中聚集,并且冻干的 DOX 载药胶束不能在水溶液中重新分散。在所合成的所有聚合物中,具有无规形式的 8 个酸/脲基的 1b 具有最佳性能。体外释放研究表明,1b 胶束中 DOX 的释放持续 7 小时以上,没有明显的初始突释。MTT 测定表明该聚合物对 HepG2 和 HEK293 细胞没有毒性。重要的是,载有 DOX 的胶束对 HepG2 细胞具有很强的抑制作用,IC(50)为 0.26mg/L,与游离 DOX(IC(50):0.20mg/L)相当。此外,与静脉注射后游离 DOX 制剂相比,静脉注射后在测试小鼠的心脏组织中 1b 载药胶束的 DOX 含量较低。这些发现表明 1b 胶束可能是一种有前途的载体制剂,可用于输送含有氨基的抗癌药物。